BioSpace News Archive

ViaDerma, Inc., announced they are nearing the end of their discussions with a major healthcare network to finalize an initial order for the Company’s wound care product, Vitastem.

Knopp Biosciences LLC announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference.

Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m. ET on Thursday, May 20

Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients with cancer, announced the appointment of Ciara Kennedy, Ph.D., M.B.A. to its board of directors.

On-track to initiate clinical development of EDP2939 in 2022

Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY® and TWYNEO®

AK-OTOF granted both Orphan Drug Designation and Rare Pediatric Disease Designation by FDA and is on track for planned IND submission in first half of 2022

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call.

Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19 ARDS

Akero Therapeutics, Inc., a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis, reported first quarter financial results for the period ending March 31, 2021.